Medico Remedies closes FY26 with 37% revenue growth, no surprises
Audited numbers confirm export-driven momentum but offer no new catalyst for a nano-cap that had already telegraphed its trajectory.
What's new
- Revenue rose 37% YoY to ₹206.38 cr, net profit up 30% to ₹13.12 cr.
- Audit opinion unmodified; no exceptional items or guidance changes.
- Results are a routine confirmation of already-anticipated performance.
Why it matters
For a nano-cap, the growth is solid, but the filing is a regulatory formality. The export-led momentum has been visible for quarters, and with no surprise or guidance revision, this is a non-event for the market.
What we're watching
- Whether export orders sustain in FY27 as the base widens.
- Any margin or capacity updates in the coming quarters.
The full read
Medico Remedies closed FY26 with revenue of ₹206.38 crore, up 37% year-on-year, and net profit of ₹13.12 crore, up 30%. The numbers are a clean confirmation of the export-driven growth telegraphed through prior quarterly disclosures. An unmodified audit opinion and the absence of exceptional items or guidance changes make this a routine regulatory filing rather than a catalyst. The next test is whether the same pace is sustainable as the base widens in FY27. For now, the company delivered what it said it would — no more, no less.